Synlogic, Inc. (SYBX) Announces Merger with Caldera Therapeutics

What Happened
Synlogic, Inc. (filed 8‑K July 29, 2026; Merger Agreement dated July 28, 2026) announced it entered into a definitive Merger Agreement with Caldera Therapeutics and Sonic Holdco that will merge both companies into subsidiaries of Sonic Holdco and issue shares of the combined company’s common stock. The transaction is structured to qualify as a tax‑free reorganization and is conditioned on customary items including Synlogic stockholder approval, Caldera stockholder approval, Nasdaq listing of the Parent shares and effectiveness of a Form S‑4 registration statement. Caldera also executed a Securities Purchase Agreement for a planned concurrent financing of approximately $278.0 million.

Key Details

• Pro forma ownership (assuming $278M financing): Caldera pre‑merger equity ~62.8%, Synlogic pre‑merger equity ~2.3%, Investors in the financing ~34.9% (fully diluted, treasury stock method).
• Valuation assumptions used in the filing: Synlogic valued at $18.0M (assuming $6.0M net cash at closing); Caldera valued at $500.0M.
• Closing conditions include Synlogic stockholder approval, Caldera written consents, Nasdaq approval for Parent common stock, at least $278.0M cash from the Concurrent Financing, and Form S‑4 effectiveness.
• Other deal terms: potential termination fees (Caldera $5.0M; Synlogic $1.0M), support agreements from major stockholders (Synlogic ~50.9% support; Caldera ~72.6% support), 180‑day lock‑ups for certain Caldera insiders, and a warrant amendment lowering Synlogic warrant exercise price to $0.70 and removing a cash redemption right.

Why It Matters
This transaction would combine Synlogic with a better‑capitalized Caldera and outside Investors, substantially diluting current Synlogic equityholders (Synlogic pre‑merger holders are projected to own a small percentage of the combined company under the stated assumptions). The deal depends on a large concurrent $278M financing, regulatory/listing approvals and stockholder votes, so it is not final until those conditions are satisfied. The warrant amendment materially lowers the exercise price of existing Synlogic warrants (making them more likely to be exercised), which could further affect Synlogic equity value and dilution. Retail investors should watch for Synlogic’s proxy statement, the S‑4 filing, and vote timing and outcomes.